Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma
Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Metastatic Squamous Cell Carcinoma of the Oropharynx
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7
Metastatic Squamous Cell Carcinoma of the Hypopharynx

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Placebo
Other: Pharmacological Study
Other: Quality-of-Life Assessment

First Posted Date: 2010-02-08

Last Posted Date: 2024-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 123

Registration Number: NCT01064479

Locations: 🇺🇸
MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
MD Anderson Regional Care Center-The Woodlands, The Woodlands, Texas, United States

and more 2 locations

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

Not Applicable

Completed

Conditions: Advanced Non-squamous Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Bevacizumab 7.5 mg/kg
Drug: Bevacizumab 15 mg/kg

First Posted Date: 2010-02-05

Last Posted Date: 2019-11-18

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT01063283

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
North Shore University Health System, Evanston, Illinois, United States

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: veliparib (ABT-888)
Drug: carboplatin
Drug: gemcitabine

First Posted Date: 2010-02-05

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 79

Registration Number: NCT01063816

A Study in Advanced Solid Tumors

Phase 2

Completed

Conditions: Solid Tumor

Interventions: Drug: Cetuximab
Drug: Carboplatin
Drug: 5 - FU

First Posted Date: 2010-02-05

Last Posted Date: 2019-09-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT01063075

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada

and more 4 locations

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: vadimezan

First Posted Date: 2010-01-27

Last Posted Date: 2013-04-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 17

Registration Number: NCT01057342

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Spitalzentrum Biel, Biel, Switzerland
🇨🇭
Saint Claraspital AG, Basel, Switzerland

and more 9 locations

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Adenocarcinoma

First Posted Date: 2010-01-20

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT01051934

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: carboplatin
Drug: RAD 001
Drug: prednisone
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2010-01-18

Last Posted Date: 2020-12-01

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01051570

Locations: 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Northshore University Health System, Evanston, Illinois, United States

and more 1 locations

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer, Metastatic

Interventions: Drug: Iniparib
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2010-01-11

Last Posted Date: 2014-01-14

Lead Sponsor: Sanofi

Target Recruit Count: 163

Registration Number: NCT01045304

Locations: 🇫🇷
Sanofi-Aventis Investigational Site Number 250001, Toulouse, France
🇦🇺
Sanofi-Aventis Investigational Site Number 036003, Westmead, Australia
🇫🇷
Sanofi-Aventis Investigational Site Number 250005, Besancon Cedex, France

and more 17 locations

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Panitumumab

First Posted Date: 2010-01-05

Last Posted Date: 2016-05-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 70

Registration Number: NCT01042288

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 10 locations

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Phase 2

Conditions: Ovarian Gynandroblastoma
Ovarian Sertoli-Leydig Cell Tumor
Ovarian Sex Cord Tumor With Annular Tubules
Ovarian Sex Cord-Stromal Tumor
Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified
Ovarian Steroid Cell Tumor
Ovarian Granulosa Cell Tumor

Interventions: Biological: Bleomycin Sulfate
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Drug: Etoposide Phosphate
Drug: Paclitaxel

First Posted Date: 2010-01-05

Last Posted Date: 2022-01-25

Lead Sponsor: GOG Foundation

Target Recruit Count: 63

Registration Number: NCT01042522

Locations: 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 216 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy